The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Take breast cancer as an example. The sensitivity of traditional ultrasound screening for breast cancer can be 76%. While with the blood-based mRNA diagnostic method, the sensitivity could be 80.6%. mRNA-based disease diagnostic technologies allow quantitive measurement of mRNA in the certain samples, such as leukemia As some technologies such as RNA-seq can provide the entire transcriptome of individual, the mRNA-based disease diagnosis can be developed in the landscape of personalized medicine. In HER-2 breast cancer, detection of ERBB2 mRNA expression levels is helpful in predicting response to anti-HER2-based treatments. As mentioned above, the mRNA-based disease diagnostic technology is more sensitive and specific to certain diseases. Even though there is no obvious symptom, the mRNA-based disease diagnostic technology can serve as screening method for early changes in RNA levels. High serum metadherin mRNA expression was observed in colorectal cancer and associated with poorly differentiated histological grades
Protomastigineae, in which absorption of food-particles in holozoic nutrition occurs at a localised point of the cell surface, often at a cytostome, although many groups were merely saprophytes; it included the majority of colourless flagellates, and even many "apochlorotic" algae; Pantostomatineae (or Rhizomastigineae), in which the absorption takes place at any point on the cell surface; roughly corresponds to "amoeboflagellates"; Distomatineae, a group of binucleate "double individuals" with symmetrically distributed flagella and, in many species, two symmetrical mouths; roughly corresponds to current Diplomonadida. Presently, these groups are known to be highly polyphyletic. In modern classifications of the protists, the principal flagellated taxa are placed in the following eukaryote groups, which include also non-flagellated forms (where "A", "F", "P" and "S" stands for autotrophic, free-living heterotrophic, parasitic and symbiotic, respectively):
==== Pallotta and Celluloid Dreams ==== Tommy Pallotta, who produced the film adaptation of Dick's novel A Scanner Darkly, said in an interview in July 2006 that he "still [had] the option for Ubik" and wanted to "make a live action feature from it". In 2007, Dick's daughter, Isa Dick Hackett, said that the film adaptation of Ubik was at an advanced stage of negotiations. In May 2008, the film was optioned by Celluloid Dreams, to be produced by Hengameh Panahi for Celluloid Dreams and Isa Dick Hackett for Electric Shepherd Productions. It was slated to enter production in early 2009, but never materialised.
Sources: en.wikipedia.org
=== Ligament and tendon repair === Autologous stem cell-based treatments for ligament injury, tendon injury, osteoarthritis, osteochondrosis, and sub-chondral bone cysts have been commercially available to practicing veterinarians to treat horses since 2003 in the United States and since 2006 in the United Kingdom. Autologous stem cell based treatments for tendon injury, ligament injury, and osteoarthritis in dogs have been available to veterinarians in the United States since 2005. Over 3000 privately owned horses and dogs have been treated with autologous adipose-derived stem cells. The efficacy of these treatments has been shown in double-blind clinical trials for dogs with osteoarthritis of the hip and elbow and horses with tendon damage. Race horses are especially prone to injuries of the tendon and ligaments. Conventional therapies are very unsuccessful in returning the horse to full functioning potential. Natural healing, guided by the conventional treatments, leads to the formation of fibrous scar tissue that reduces flexibility and full joint movement. Traditional treatments prevented a large number of horses from returning to full activity and also have a high incidence of re-injury due to the stiff nature of the scarred tendon. Introduction of both bone marrow and adipose derived stem cells, along with natural mechanical stimulus promoted the regeneration of tendon tissue. The natural movement promoted the alignment of the new fibers and tendocytes with the natural alignment found in uninjured tendons.
Foodborne diseases, emerging, WHO, Fact sheet N°124, revised January 2002 Foodborne illness information pages Archived December 30, 2019, at the Wayback Machine, NSW Food Authority Food safety and foodborne illness, WHO, Fact sheet N°237, revised January 2002 UK Health protection Agency US PulseNet Food poisoning from NHS Direct Online Food Safety Network hosted at the University of Guelph, Canada. Food Standard Agency website
Since the thermal conductivity of ice is so small (1.6 - 2.4 W mK−1) compared with most every other ceramic (ex. Al2O3= 40 W mK−1), the growing ice will have a significant insulative effect on the localized thermal conditions within the slurry. This can be illustrated using simple resistor elements.
Sources: en.wikipedia.org
=== Mechanical engineering === When a periodic force is applied to a mechanical system, it will typically reach a steady state after going through some transient behavior. This is often observed in vibrating systems, such as a clock pendulum, but can happen with any type of stable or semi-stable dynamic system. The length of the transient state will depend on the initial conditions of the system. Given certain initial conditions, a system may be in steady state from the beginning.
Fossil dinosaur eggshells, like modern bird and reptile eggshells, are made up of calcium carbonate crystal units. The basic arrangement and structure of these eggshell units (called the ultrastructure) is used to divide fossil eggs into several basic types, including the spherulitic, prismatic, and ornithoid basic types, which contain dinosaurs. Dinosaur eggs further classified by the microstructural aspects of the crystalline structure of the eggshell units and by the type of their pores and their shell ornamentation.
In the course of the 1960s and 1970s, Cold War participants struggled to adjust to a new, more complicated pattern of international relations in which the world was no longer divided into two clearly opposed blocs. From the beginning of the post-war period with American help, Western Europe and Japan rapidly recovered from the destruction of World War II and sustained strong economic growth throughout the 1950s and 1960s, with per capita GDPs approaching those of the United States, while Eastern Bloc economies stagnated.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.